drugset

drugset / Trial / NCT01094769

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

NCT01094769 ↗

Phase 4 Completed 48 enrolled Baker Heart and Diabetes Institute

RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine whether moxonidine is effective in reducing urine albumin levels in patients with diabetic kidney disease.

Timeline

Start: 2011-04
Primary completion: 2020-01
Completion: 2020-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Moxonidine	Small molecule	0.6 mg	—

Indications